Anti-cancer drugs trade margins are capped at 30%, leading to significant price reductions for consumers.
Cancer drug prices may fall significantly, offering real savings for patients and healthcare systems.
Generic drug price-fixing claims result in a $96M settlement involving six pharmaceutical companies.